#95 Landmark Clinical Evidence
Peer-reviewed human research with direct implications for cannabis medicine practice.
# Cannabis Oral Mucosal Delivery Summary This review examines formulation and fabrication strategies for delivering cannabinoids through oral mucosal routes, including sublingual, buccal, and oromucosal approaches, which offer potential advantages over gastrointestinal absorption such as faster onset, reduced first-pass metabolism, and improved bioavailability. Current challenges in mucosal delivery include cannabinoid lipophilicity, poor water solubility, and inconsistent absorption, which existing formulation technologies such as nanoparticles, lipid-based systems, and permeation enhancers attempt to address. The review emphasizes that optimizing mucosal delivery could enable more precise dosing and predictable therapeutic effects compared to traditional oral or inhaled cannabis products, particularly important for patients requiring consistent symptom management. Standardization of mucosal cannabinoid formulations remains limited in the current market, where most available products lack rigorous bioavailability data or quality control measures. For clinicians counseling patients on cannabis products, understanding that oral mucosal formulations represent an emerging category with variable efficacy and reliability is essential when considering them as treatment options. Patients and providers should recognize that while mucosal delivery holds promise for improved cannabinoid pharmacokinetics, most commercially available mucosal cannabis products have not undergone the formulation optimization described in this research, making standardized pharmaceutical options preferable when available.
“The oral mucosal delivery systems we’re seeing in the literature now represent a genuine clinical advance because they bypass first-pass hepatic metabolism and give us more predictable pharmacokinetics, which means I can actually titrate dosing for my patients instead of guessing at effects. When formulation science catches up to clinical demand, we move from anecdote-based medicine to evidence-based medicine, and that’s what patients deserve.”
💊 As oral mucosal delivery systems for cannabinoids advance beyond traditional smoking and ingestion, clinicians should recognize both the promise and limitations of these emerging formulations. These delivery methods—including sublingual sprays, lozenges, and buccal films—offer potential advantages such as faster onset, improved bioavailability, and reduced first-pass metabolism compared to swallowed cannabis products, which may be relevant for patients requiring rapid symptom relief or those with gastrointestinal disorders. However, substantial variability exists in cannabinoid absorption across individuals due to differences in oral pH, salivary flow, mucosal thickness, and concurrent medications, making dosing standardization challenging in clinical practice. The lack of established bioequivalence standards and limited long-term safety data for these formulations means providers should counsel patients that pharmacokinetic predictability remains inferior to many conventional pharmaceuticals. Clinicians considering cannabinoid recommendations should
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: